Mirae Asset Global Investments Co. Ltd. grew its stake in SAGE Therapeutics Inc (NASDAQ:SAGE) by 19.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,437 shares of the biopharmaceutical company’s stock after purchasing an additional 1,391 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in SAGE Therapeutics were worth $1,192,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Principal Financial Group Inc. boosted its holdings in SAGE Therapeutics by 3.2% in the first quarter. Principal Financial Group Inc. now owns 12,406 shares of the biopharmaceutical company’s stock valued at $1,998,000 after purchasing an additional 382 shares during the last quarter. Bank of Montreal Can boosted its holdings in SAGE Therapeutics by 1,251.7% in the second quarter. Bank of Montreal Can now owns 5,042 shares of the biopharmaceutical company’s stock valued at $789,000 after purchasing an additional 4,669 shares during the last quarter. Aperio Group LLC purchased a new position in SAGE Therapeutics in the second quarter valued at about $324,000. Raymond James Financial Services Advisors Inc. boosted its holdings in SAGE Therapeutics by 93.6% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 4,774 shares of the biopharmaceutical company’s stock valued at $747,000 after purchasing an additional 2,308 shares during the last quarter. Finally, Smith Asset Management Group LP boosted its holdings in SAGE Therapeutics by 15.7% in the second quarter. Smith Asset Management Group LP now owns 5,160 shares of the biopharmaceutical company’s stock valued at $808,000 after purchasing an additional 700 shares during the last quarter.

A number of research analysts recently commented on the company. BidaskClub raised SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, August 30th. Oppenheimer set a $170.00 price target on SAGE Therapeutics and gave the company a “buy” rating in a report on Sunday, November 4th. Canaccord Genuity set a $220.00 price target on SAGE Therapeutics and gave the company a “buy” rating in a report on Thursday, November 1st. Cowen reissued a “buy” rating and issued a $207.00 price target on shares of SAGE Therapeutics in a report on Thursday, November 1st. Finally, LADENBURG THALM/SH SH set a $235.00 price target on SAGE Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 31st. Two analysts have rated the stock with a sell rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $202.00.

Shares of NASDAQ SAGE opened at $101.99 on Friday. SAGE Therapeutics Inc has a 52-week low of $99.50 and a 52-week high of $195.97. The company has a market cap of $4.72 billion, a price-to-earnings ratio of -14.39 and a beta of 2.72.

SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported ($2.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.41) by ($0.22). During the same quarter in the previous year, the business posted ($1.97) earnings per share. Equities research analysts expect that SAGE Therapeutics Inc will post -7.75 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was posted by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/mirae-asset-global-investments-co-ltd-raises-holdings-in-sage-therapeutics-inc-sage/2689661.html.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Read More: How Does the Quiet Period Work?

Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.